ATE477000T1 - Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen - Google Patents

Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen

Info

Publication number
ATE477000T1
ATE477000T1 AT03789883T AT03789883T ATE477000T1 AT E477000 T1 ATE477000 T1 AT E477000T1 AT 03789883 T AT03789883 T AT 03789883T AT 03789883 T AT03789883 T AT 03789883T AT E477000 T1 ATE477000 T1 AT E477000T1
Authority
AT
Austria
Prior art keywords
preventing
relates
treating diseases
nucleic acid
methods
Prior art date
Application number
AT03789883T
Other languages
English (en)
Inventor
Hideki Garren
Peggy P Ho
Lawrence Steinman
Original Assignee
Bayhill Therapeutics Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc, Univ Leland Stanford Junior filed Critical Bayhill Therapeutics Inc
Application granted granted Critical
Publication of ATE477000T1 publication Critical patent/ATE477000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT03789883T 2002-11-21 2003-11-21 Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen ATE477000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42864302P 2002-11-21 2002-11-21
PCT/US2003/037157 WO2004047734A2 (en) 2002-11-21 2003-11-21 Methods and immune modulatory nucleic acid compositions for preventing and treating disease

Publications (1)

Publication Number Publication Date
ATE477000T1 true ATE477000T1 (de) 2010-08-15

Family

ID=32393438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789883T ATE477000T1 (de) 2002-11-21 2003-11-21 Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen

Country Status (15)

Country Link
US (1) US7811813B2 (de)
EP (5) EP2353614A1 (de)
JP (2) JP4750419B2 (de)
CN (2) CN101955976A (de)
AT (1) ATE477000T1 (de)
AU (2) AU2003294400B2 (de)
CA (1) CA2507249A1 (de)
DE (1) DE60333786D1 (de)
DK (1) DK1569696T3 (de)
ES (1) ES2350576T3 (de)
IL (1) IL168715A (de)
NZ (1) NZ540276A (de)
PT (1) PT1569696E (de)
SI (1) SI1569696T1 (de)
WO (1) WO2004047734A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE252596T1 (de) * 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US20100130593A1 (en) * 2006-06-13 2010-05-27 Bayhill Therapeutics, Inc. Methods and immune modulator nucleic acid compositions for preventing and treating disease
BRPI0720035A2 (pt) * 2006-12-06 2019-05-07 Medimmune, Llc métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
JP5411129B2 (ja) * 2007-05-03 2014-02-12 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
JP5749492B2 (ja) 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
BR112012032240A2 (pt) 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
US20130236453A1 (en) * 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP3799882A1 (de) 2016-11-01 2021-04-07 Novo Nordisk A/S Tolerogener dna-impfstoff
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4425732A (en) 1981-06-17 1984-01-17 Kania Tadeusz E Animal trap
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5218103A (en) 1988-05-26 1993-06-08 University Patents, Inc. Nucleoside thiophosphoramidites
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0648271B1 (de) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ATE328890T1 (de) * 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1997046253A2 (en) 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
EP1537877A3 (de) * 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulierende Oligonucleotidekonjugate
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE252596T1 (de) * 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001229472A1 (en) * 2000-01-10 2001-07-24 Elim Biopharmaceuticals, Inc. Novel plasmid dna vectors
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
EP2301553A1 (de) 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynukleotidtherapie
CN1820020B (zh) * 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US20100048679A1 (en) * 2006-06-13 2010-02-25 Bayhill Therapeutics, Inc. Polynucleotide therapy
WO2008013782A2 (en) * 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions

Also Published As

Publication number Publication date
WO2004047734A2 (en) 2004-06-10
US20050261215A1 (en) 2005-11-24
PT1569696E (pt) 2010-11-11
EP2298360A3 (de) 2011-07-13
US7811813B2 (en) 2010-10-12
AU2003294400B2 (en) 2008-12-18
JP2006514933A (ja) 2006-05-18
ES2350576T3 (es) 2011-01-25
CA2507249A1 (en) 2004-06-10
DE60333786D1 (de) 2010-09-23
EP1569696A2 (de) 2005-09-07
CN100546657C (zh) 2009-10-07
DK1569696T3 (da) 2010-11-15
SI1569696T1 (sl) 2010-12-31
IL168715A (en) 2011-09-27
EP2322186A2 (de) 2011-05-18
EP2329827A2 (de) 2011-06-08
CN101955976A (zh) 2011-01-26
EP2298360A2 (de) 2011-03-23
WO2004047734A3 (en) 2004-08-12
CN1777447A (zh) 2006-05-24
AU2009201102A1 (en) 2009-04-09
EP2329827A3 (de) 2011-07-13
AU2003294400A1 (en) 2004-06-18
EP1569696A4 (de) 2006-01-11
EP2353614A1 (de) 2011-08-10
EP2322186A3 (de) 2011-07-13
EP1569696B1 (de) 2010-08-11
JP2011148801A (ja) 2011-08-04
NZ540276A (en) 2007-12-21
JP4750419B2 (ja) 2011-08-17

Similar Documents

Publication Publication Date Title
ATE477000T1 (de) Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen
WO2003045316A3 (en) Polynucleotide therapy
WO2003103586A3 (en) METHOD OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES USING COMBINATIONS OF INHIBITOR OLIGONUCLEOTIDES AND SMALL IMMUNOSTIMULATORY NUCLEIC ACID ANTAGONIST MOLECULES
DE69935507D1 (de) Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2002006339A3 (en) Proteins and nucleic acids encoding same
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2007147007A3 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
IL169367A0 (en) Defensin proteins
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2003055912A3 (en) Secreted proteins
ATE348161T1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
DE60137459D1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
WO2002026826A3 (en) Proteins and nucleic acids encoding same
WO2005030985A3 (en) Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases
WO2002058716A3 (en) Treatment of inflammatory bowel disease using growth factors
WO2005019427A3 (en) Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
WO2004043353A3 (en) Compositions and methods for treating acute myeloid leukemia
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2002062845A3 (en) Adhesion molecules
WO2003054178A3 (en) Metalloprotease proteins
WO2004035626A8 (en) Alpha macroglobulin protein family members
WO2004026905A3 (en) Transporter/channel proteins
WO2002088341A3 (en) P450 proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569696

Country of ref document: EP